NitroMed to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
NitroMed zu myNews hinzufügen Was ist das?
NitroMed, Inc. (NASDAQ: NTMD), announced today that Kenneth M. Bate,
President and Chief Executive Officer of NitroMed is scheduled to
present at the Acumen BioFin Rodman & Renshaw 9th
Annual Healthcare Conference on Monday, November 5, at 12:40 p.m. EDT at
the New York Palace Hotel in New York City.
NitroMed’s presentation at the conference will
be webcast live, and will also be archived on the Company’s
website (http://www.nitromed.com)
for an indefinite period of time following the event.
About NitroMed
NitroMed, Inc. of Lexington, Massachusetts is an emerging pharmaceutical
company and the maker of BiDil®
(isosorbide dinitrate/hydralazine hydrochloride), an orally administered
medicine available in the United States for the treatment of heart
failure in self-identified black patients. In this population, BiDil is
indicated as an adjunct to current standard therapies such as
angiotensin converting enzyme (ACE) inhibitors and beta blockers. There
is little experience in patients with New York Heart Association Class
IV heart failure. BiDil was approved by the U.S. Food and Drug
Administration, primarily on the basis of efficacy data from the Company’s
landmark A-HeFT (African American Heart Failure Trial) clinical trial
and is marketed by NitroMed through a specialty medicines sales
organization.
For full prescribing information, visit: www.BiDil.com.
BiDil is a registered trademark of NitroMed, Inc.
